Cytek Biosciences, Inc. (CTKB) stock
CTKBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/309% below fair value
$5.70+0.07 (+1.24%)
Close on Nov 17, 2026Market cap $740.91MP/E –Yield –
Cytek Biosciences cash
Cash and short-term investments held at the end of each period.
Cytek Biosciences's cash was $73.85M at Jun 30, 2026. For fiscal 2025 it was $90.85M, down 8.0% from the year before. The highest annual figure on record is $364.62M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $90.85M | -8.0% |
| FY2024 | Dec 31, 2024 | $98.75M | -41.1% |
| FY2023 | Dec 31, 2023 | $167.63M | -44.0% |
| FY2022 | Dec 31, 2022 | $299.50M | -17.9% |
| FY2021 | Dec 31, 2021 | $364.62M | +119.5% |
| FY2020 | Dec 31, 2020 | $166.12M | +444.8% |
| FY2019 | Dec 31, 2019 | $30.49M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $73.85M | -2.2% |
| Q1 FY2026 | Mar 31, 2026 | $65.67M | -31.1% |
| Q4 FY2025 | Dec 31, 2025 | $90.85M | -8.0% |
| Q3 FY2025 | Sep 30, 2025 | $93.28M | -42.5% |
| Q2 FY2025 | Jun 30, 2025 | $75.47M | -57.6% |
| Q1 FY2025 | Mar 31, 2025 | $95.30M | -43.7% |
| Q4 FY2024 | Dec 31, 2024 | $98.75M | -41.1% |
| Q3 FY2024 | Sep 30, 2024 | $162.30M | -0.8% |
| Q2 FY2024 | Jun 30, 2024 | $177.92M | +35.3% |
| Q1 FY2024 | Mar 31, 2024 | $169.14M | +27.8% |
| Q4 FY2023 | Dec 31, 2023 | $167.63M | -44.0% |
| Q3 FY2023 | Sep 30, 2023 | $163.63M | -52.1% |
| Q2 FY2023 | Jun 30, 2023 | $131.54M | -62.4% |
| Q1 FY2023 | Mar 31, 2023 | $132.39M | -63.5% |
| Q4 FY2022 | Dec 31, 2022 | $299.50M | -17.9% |
| Q3 FY2022 | Sep 30, 2022 | $341.52M | -9.4% |
| Q2 FY2022 | Jun 30, 2022 | $349.89M | +118.9% |
| Q1 FY2022 | Mar 31, 2022 | $362.51M | +115.0% |
| Q4 FY2021 | Dec 31, 2021 | $364.62M | +119.5% |
| Q3 FY2021 | Sep 30, 2021 | $376.77M | +960.5% |
| Q2 FY2021 | Jun 30, 2021 | $159.85M | +352.5% |
| Q1 FY2021 | Mar 31, 2021 | $168.58M | +452.9% |
| Q4 FY2020 | Dec 31, 2020 | $166.12M | – |
| Q3 FY2020 | Sep 30, 2020 | $35.53M | – |
| Q2 FY2020 | Jun 30, 2020 | $35.32M | – |
| Q4 FY2019 | Dec 31, 2019 | $30.49M | – |
See a number that looks wrong?